More likely path is to pull trigger on deal in US.
Remember it was SW egging on PR to take on dilution over striking deal too early back in 2021. What both these gooses forgot to consider was the impact of the overall clinical strategy being so comprehensive its (1) delayed the engagement process and vetting of potential partners (2) cost multiples of what was originally forecast. Something a Board with a proper fiduciary governance framework would consider.
I suspect SW will be signing from new (non dilutive) hymn sheet going forward. As someone mentioned always back self interest.
Ann: PAR Appoints Business Development Consultant, page-111
-
- There are more pages in this discussion • 217 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $261.4K | 990.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 9445 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |